immunoglobulin lambda like polypeptide 5Genealiases: IGLV · VL-MAR
Q-omics provides the consensus-scored IGLL5 profile across patient tissues and cancer cell-line models. IGLL5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGLL5 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, IGLL5 protein abundance shows 19,781 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where IGLL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLL5 survival associations across molecular data types. IGLL5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLL5 RNA expression–survival associations across cancer types. High IGLL5 expression shows unfavorable associations in KIRC and GBM, but favorable associations in HNSC, SKCM, BRCA and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGLL5 RNA expression.
This table summarizes IGLL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for IGLL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLL5 shows lower tumor expression in COAD, READ, BRCA and LIHC and higher tumor expression in LUAD and KIRC. The COAD box plot shows higher IGLL5 RNA expression in normal versus tumor tissue (log2 FC = −3.998, t-test p < 0.001).
This table shows molecular features associated with IGLL5 in patient tissues and cancer cell lines. In patient samples, IGLL5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IGLL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
